VC firms
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Overview
Investment Type
Venture Capital
Mentions in press and media 25
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 19, 2013 | What’s special about the 3 biotechs in the top 10 for Q2 venture investments? | But let’s look a little more closely at the those three biotechnology companies and what they say about what is drawing investor attention. Two of the three provide valuable services to other life science companies. The third has a heart fa... |
| Mar 21, 2013 | Pediatric drug developer with treatment for infantile jaundice could reduce readmissions | InfaCare’s drug Stanate was licensed from Rockefeller University. A heme oxygenase inhibitor, Stanate prevents the breakdown of heme in the body. It is designed to significantly reduce the body’s production of bilirubin over a six- to eight... |
| Feb 26, 2013 | DecImmune Therapeutics Completes $2.25M Equity Financing | DecImmune Therapeutics, a Cambridge, MA-based company that develops novel peptides and antibodies for acute, tissue damaging inflammation in myocardial infarction, burns, and other conditions involving vascular injury and reperfusion, compl... |
| Feb 22, 2013 | Antibody could reduce longterm effects of myocardial infarction, cut readmissions | Walter Newman is the chief scientific officer for Decimmune and serves on the company’s business and advisory team. In a phone interview with MedCity News, Newman said the company had recently raised $2.25 million to help advance its treatm... |
| Dec 17, 2012 | Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised $32 million in a Series C round. Among the company’s institutional investors are Clarus Ventures, HealthCare Ventures, Quaker Partners, Novi... |
| Apr 16, 2012 | Biomarker test firm Cleveland HeartLab eyes health and wellness market | “We’ve become a recognized leader in the identification and prevention of chronic disease ,” Orville said. “Now we have the ability to focus more on other important markets, such as health and wellness companies.” Cleveland HeartLab recentl... |
| Apr 2, 2012 | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | Last year, it was granted a five-year research grant valued up to $196 million by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to fund the development of seasonal and ... |
| Aug 22, 2011 | Cleveland HeartLab Completes $18.4M Series B Financing Round | Cleveland HeartLab Inc. (CHL), a specialty clinical laboratory and disease management company, completed an $18.4m Series B financing round. The investment was led by Excel Venture Management and HealthCare Ventures, with participation from... |
| Aug 22, 2011 | Biomarker test firm Cleveland HeartLab closes $18.4M investment | The round was led by Excel Venture Management of Boston and HealthCare Ventures of Cambridge, Massachusetts, with participation from existing investors. Cleveland HeartLab is a clinical reference laboratory that does an array of lipid and i... |
Show more
Reviews 0
FAQ about HealthCare Ventures
What has the press written about HealthCare Ventures?
Parsers VC has collected 25 articles mentioning HealthCare Ventures, among them “What’s special about the 3 biotechs in the top 10 for Q2 venture investments?” (Jul 19, 2013) and “Pediatric drug developer with treatment for infantile jaundice could reduce readmissions” (Mar 21, 2013).
Is HealthCare Ventures still active?
Yes, HealthCare Ventures is active; its latest activity on Parsers VC dates from Oct 30, 2013.